A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables

Oncotarget

Volumn 2, Issue 7, 2011, Pages 529-537

  Endesfelder, David ^a   McGranahan, Nicholas ^a,b   Birkbak, Nicolai J ^c,d   Szallasi, Zoltan ^d,e   Kschischo, Maik ^f   Graham, Trevor A ^a   Swanton, Charles ^a,g  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^f UNIVERSITY OF APPLIED SCIENCES   (Germany)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Age; Breast cancer; Chromosomal instability; Histopathological parameters

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HER2 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CHROMOSOMAL INSTABILITY; GENE EXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; TUMOR VOLUME; AGED; BREAST TUMOR; CHEMISTRY; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; META ANALYSIS; MIDDLE AGED; ONSET AGE; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHROMOSOMAL INSTABILITY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 84856213654     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.298     Document Type: Article

References (36)

1. Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young breast cancer patients have worse outcomes? The Journal of surgical research. 2003; 113:109-113.
2. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, Shamseddine AI. Effects of young age at presentation on survival in breast cancer. BMC cancer. 2006; 6:194.
3. Jayasinghe UW, Taylor R, Boyages J. Is age at diagnosis an independent prognostic factor for survival following breast cancer? ANZ J Surg. 2005; 75:762-767.
4. Gabriel CA, Domchek SM. Breast cancer in young women. Breast cancer research: BCR. 2010; 12:212.
5. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut. 2008; 57:941-950.
6. Sotillo R, Schvartzman JM, Socci ND, Benezra R. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature. 2010; 464:436-440.
7. Janssen A, Kops GJ, Medema RH. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A. 2009; 106:19108-19113.
8. Lee A, Endesfelder D, Rowan A, Walther A, Birkbak N, Futreal AP, Downward J, Szallasi Z, Tomlinson I, Kschischo M, Swanton C. Chromosomal Instability Confers Intrinsic Multi-Drug Resistance. Cancer Res. 2011; 71:1858-1870.
9. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell. 2007; 11:25-36.
10. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends in cell biology. 1999; 9:M57-60.
11. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 2011.
12. Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bundgen NK, Nicorici D, Kronenwett U, Rathnagiriswaran S, Mettu RK, Ma Y, Kruger S, Bruch HP, Auer G, Guo NL, Ried T. The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer. 2009; 124:1552-1564.
13. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006; 38:1043-1048.
14. Geigl JB, Langer S, Barwisch S, Pfleghaar K, Lederer G, Speicher MR. Analysis of gene expression patterns and chromosomal changes associated with aging. Cancer research. 2004; 64:8550-8557.
15. Ly DH, Lockhart DJ, Lerner RA, Schultz PG. Mitotic misregulation and human aging. Science. 2000; 287:2486-2492.
16. Richardson B. Impact of aging on DNA methylation. Ageing research reviews. 2003; 2:245-261.
17. Hackett JA, Feldser DM, Greider CW. Telomere dysfunction increases mutation rate and genomic instability. Cell. 2001; 106:275-286.
18. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, DePinho RA. Telomere dysfunction promotes nonreciprocal translocations and epithelial cancers in mice. Nature. 2000; 406:641-645.
19. Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, Foekens JA, Zhang Y, Wang Y, Marcom K, Marks JR, Mukherjee S, Nevins JR, Blackwell KL, Potti A. Agespecific differences in oncogenic pathway deregulation seen in human breast tumors. PloS one. 2008; 3:e1373.
20. Thomas GA, Leonard RC. How age affects the biology of breast cancer. Clinical oncology. 2009; 21:81-85.
21. Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL, Klauber-DeMore N, Perou CM. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29:e18-20.
22. Eppenberger-Castori S, Moore DH, Jr., Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC. Ageassociated biomarker profiles of human breast cancer. The international journal of biochemistry & cell biology. 2002; 34:1318-1330.
23. Yau C, Fedele V, Roydasgupta R, Fridlyand J, Hubbard A, Gray JW, Chew K, Dairkee SH, Moore DH, Schittulli F, Tommasi S, Paradiso A, Albertson DG, Benz CC. Aging impacts transcriptomes but not genomes of hormonedependent breast cancers. Breast cancer research: BCR. 2007; 9:R59.
24. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006; 10:529-541.
25. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005; 102:13550-13555.
26. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365:671-679.
27. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98:262-272.
28. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two populationbased cohorts. Breast Cancer Res. 2005; 7:R953-964.
29. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008; 14:5158-5165.
30. Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat. 2008; 108:191-201.
31. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M, Hortobagyi GN, Shi L et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast cancer research: BCR. 2010; 12:R5.
32. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009; 15:68-74.
33. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006; 24:4236-4244
34. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, Andre S, Acharya CR, Mukherjee S, Cameron D et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. The lancet oncology. 2007; 8:1071-1078.
35. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Jr., Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. The lancet oncology. 2007; 8:203-211.
36. Armitage P. Tests for Linear Trends in Proportions and Frequencies. Biometrics. 1955; 11:375-386.